AstraZeneca: Rebound in 2024 with double-digit earnings growth

Key PointsAstraZeneca gained 8.95% in the past month, fueled by optimism about its 2024 earnings outlook.Rising sales of cancer and diabetes drugs are key contributors to AstraZeneca's positive performance.The company announced an acquisition in the area of cell therapies and also has a licensing deal with a company developing weight-loss treatments. 5 stocks we like better than AstraZenecaU.K.-based AstraZeneca PLC NASDAQ: AZN is up 8.95% in the past month as investors grow optimistic about the company's i ...